Loading provider…
Loading provider…
Rheumatology Physician in Colleyville, TX
NPI: 1336266964Primary Practice Location
TEXAS HEALTH HARRIS METHODIST HURST-EULESS-BEDFORD
1600 Hospital Pkwy, Bedford, TX
Primary Employer
American Arthritis & Rheumatology Associates-TX PLLC
dfwrheumatology.com
HQ Phone
Get MD Dhiman's Phone Numberphone_androidMobile
Get MD Dhiman's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMI State Medical License
TX State Medical License
TX State Medical License
2007 - 2025
MI State Medical License
2005 - 2011

American Board of Internal Medicine
Rheumatology
University of Michigan
Fellowship • Rheumatology
2005 - 2007
University of Texas Health Science Center at Houston
Residency • Internal Medicine
2003 - 2005
Calcutta National Medical College
Medical School
Until 1996
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 242 | 836 |
| 2 | 96401Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | 61 | 447 |
| 3 | 96413Infusion of chemotherapy into a vein up to 1 hour | 41 | 252 |
| 4 | J0897Injection, denosumab, 1 mg | 41 | 4,260 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 23 | 23 |
Authors: Abdul Abdellatif, Mehdi Mirsaeidi, Anca Askanase
Journal: Clin Drug Investig
Publication Date: 2023-10-04
Effect of race and ethnicity on perceptions of inflammatory bowel disease.
Authors: Darrell Finlay, Joseph Sellin
Journal: Inflamm Bowel Dis
Authors: John Reveille
Journal: Autoimmunity
Lead Sponsor: Amgen
Intervention / Treatment: OTHER: Placebo, DRUG: VIB7734
Lead Sponsor: GlaxoSmithKline
Collaborators: Iqvia Pty Ltd
Intervention / Treatment: DRUG: Placebo, BIOLOGICAL: GSK3196165 (Otilimab), DRUG: Tofacitinib 5 mg
Lead Sponsor: GlaxoSmithKline
Collaborators: Iqvia Pty Ltd
Intervention / Treatment: BIOLOGICAL: Otilimab (GSK3196165), DRUG: csDMARD(s)